NICE Single Technology Appraisal Guidance No 201 Omalizumab for
the treatment of severe persistent allergic asthma in children aged
NICE Single Technology Appraisal Guidance No
201 – Omalizumab for the treatment of asthma in
children (6 to <12 years)
This NICE Guidance was
published today, 27 October 2010. The web reference for the
appraisal and other related documents is: http://guidance.nice.org.uk/TA201
NHSScotland should note
1. Recommendations of NICE Single Technology
Appraisals (STAs) have no status in NHS Scotland.
2. NHS Boards should continue to adhere to the
The Scottish Medicines Consortium (SMC)
published a Statement of Advice (611/10) on this medication for
this indication following an abbreviated submission in April 2010.
This stated that:
Omalizumab (Xolair) is accepted
for restricted use within NHS Scotland as add-on therapy in severe
persistent allergic asthma in children 6 to <12 years of age.
Use is restricted to patients who are prescribed chronic systemic
steroids and in whom all other treatments have failed. The response
to omalizumab treatment should be assessed in all patients at 16
weeks and treatment should be discontinued in patients who have not
shown a marked improvement in overall asthma control.
Access the advice of the Scottish Medicines Consortium:
3. There is a material difference between the
recommendations of the NICE STA and the SMC. NICE did not recommend
If you need further assistance, please contact
Eleanor Brownlee in
the first instance tel 0141 225 6873
Published Date: 27 October 2010